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Abstract
Eyes Absents (EYA) are multifunctional proteins best known for their role in organogenesis. There is accumulating evidence
that overexpression of EYAs in breast and ovarian cancers, and in malignant peripheral nerve sheath tumors, correlates with
tumor growth and increased metastasis. The EYA protein is both a transcriptional activator and a tyrosine phosphatase, and
the tyrosine phosphatase activity promotes single cell motility of mammary epithelial cells. Since EYAs are expressed in
vascular endothelial cells and cell motility is a critical feature of angiogenesis we investigated the role of EYAs in this
process. Using RNA interference techniques we show that EYA3 depletion in human umbilical vein endothelial cells inhibits
transwell migration as well as Matrigel-induced tube formation. To specifically query the role of the EYA tyrosine
phosphatase activity we employed a chemical biology approach. Through an experimental screen the uricosuric agents
Benzbromarone and Benzarone were found to be potent EYA inhibitors, and Benzarone in particular exhibited selectivity
towards EYA versus a representative classical protein tyrosine phosphatase, PTP1B. These compounds inhibit the motility of
mammary epithelial cells over-expressing EYA2 as well as the motility of endothelial cells. Furthermore, they attenuate
tubulogenesis in matrigel and sprouting angiogenesis in the ex vivo aortic ring assay in a dose-dependent fashion. The anti-
angiogenic effect of the inhibitors was also demonstrated in vivo, as treatment of zebrafish embryos led to significant and
dose-dependent defects in the developing vasculature. Taken together our results demonstrate that the EYA tyrosine
phosphatase activity is pro-angiogenic and that Benzbromarone and Benzarone are attractive candidates for repurposing as
drugs for the treatment of cancer metastasis, tumor angiogenesis, and vasculopathies.
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Introduction
The Eyes Absent (EYA1-4) genes encode an unusual family of
proteins; they have both transactivation and threonine phospha-
tase [1] activities in a poorly conserved N-terminal domain and
tyrosine phosphatase activity in a well-conserved C-terminal
domain [2,3,4]. The threonine phosphatase activity has been
linked with the innate immune response, while the tyrosine
phosphatase activity is associated with cell motility [5], DNA
damage repair [6,7], and fly eye development [2,3]. Developmen-
tal defects encompassing multiple organs (including ear, kidney,
muscle, thymus) have been reported in Eya1 and Eya4 mutant
mice [8], and multi-organ birth defects are associated with EYA
mutations in humans [9,10,11,12]. In addition to the long-
recognized developmental role of the EYAs, there is growing
evidence that they are over-expressed in various adult cancers;
EYA2 (in breast [5,13] and ovarian cancer [14]) and EYA4 (in
malignant peripheral nerve sheath tumors [15]) are associated with
increased tumor size and metastasis. The tyrosine phosphatase
activity specifically promotes the motility and invasiveness of
cancer cells [16].
Evidence for a link between the EYAs and cardiovascular
developmenthasbeengrowing;mutationofEYA4isassociatedwith
dilatedcardiomyopathy[17],humanEYA1mutationsareassociated
with cardiac defects [18], there are alterations in cardiovascular
function in Eya3 mutant mice [19], and Six1
-/-Eya1
-/- mutant mice
exhibit multiple vascular anomalies [20]. However a direct link
betweenEYAandtheprocessofangiogenesishasnotbeenreported.
Moreover, because the EYAs have multiple biochemical activities,
the molecular mechanisms by which EYA might influence vascular
development remains to be established. Chemical biology has
emerged as an effective means of dissecting the cellular and
biological roles of such multifunctional proteins. However, achiev-
ing specificity among protein tyrosine phosphatases has been
a challenge for inhibitor design. In this regard the EYAs could have
an advantage since the EYA tyrosine phosphatase domain is
mechanistically unusual; it does not utilize a cysteine residue in
catalysis,asdoallotherknownproteintyrosinephosphatases(PTPs)
(reviewed in [21]). Instead, the EYAs belong to the large family of
haloacid dehalogenase (HAD) type phosphotransferases, metallo-
enzymes that employ an Aspartate as a nucleophile and another
conserved Aspartate two residues downstream as an acid catalyst
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34806[2,22]. The active site of the EYAs thus represents an unconven-
tional target for the design of small molecule PTP inhibitors.
Here we show that the uricosuric agents Benzbromarone and
Benzarone are potent inhibitors of the EYA tyrosine phosphatase.
Both compounds exhibit selectivity for EYA over a representative
classical PTP, PTP1B. They are active in cellular assays, inhibiting
the EYA-promoted motility of mammary epithelial cells as well as
endothelialcells.Furthermoreweprovideevidencethatinhibitionof
EYA attenuates angiogenesis using in vitro, ex vivo and in vivo assays.
ThisisthefirstdirectdemonstrationofarolefortheEYAproteinsin
angiogenesisandraisesthepossibilitythatinhibitionofEYAactivity
could be a useful therapeutic strategy in the treatment of tumor
angiogenesis and other vasculopathies. Additionally, since EYA
over-expression and catalytic activity is linked to tumor metastasis
and DNA damage repair, an inhibitor of the EYA tyrosine
phosphatase could be useful as an anti-metastatic agent and in the
potentiation of DNA damaging therapies.
Results
Eyes Absents are expressed in endothelial cells and
contribute to endothelial cell migration and capillary
tubule formation
Eyes absent (EYA1) plays an important role in pulmonary and
cardiac vascular morphogenesis. [23,24]. Prior to investigating
a cell-autonomous requirement of Eya in endothelial cells
function, RT-PCR was performed in order to identify which
Eya transcripts are expressed in vascular endothelial cells. mRNA
for EYA1 and EYA3 was strongly detected in human umbilical
vein endothelial cells (HUVECs) (Figure 1a). To evaluate the role
of EYA in endothelial cell function HUVECs were stably infected
with lentiviruses expressing either control shRNA (scramble
control) or an shRNA specific to EYA3. Quantitative real-time
PCR (qRT-PCR) was used to estimate the reduction of mRNA
level relative to the scramble control and showed nearly 75%
reduction in transcript level (Figure 1a). To assess the effect of
reducing EYA3 expression on cell proliferation the colorimetric
tetrazolium salt MTT assay [25], which monitors the metabolic
activity of cultured cells, was used. HUVEC-shEYA3 cells showed
a small but significant increase in proliferation compared to
control cells (Figure 1b). Next a modified Boyden chamber assay
was conducted and a significant attenuation of single cell
migration upon knockdown of EYA3 was detected (Figure 1c).
Since cell migration is critical for angiogenesis, we next examined
the effect of EYA3 levels on the morphological differentiation of
HUVECs in Matrigel. Under control conditions HUVECs formed
a network of capillary-like structures in 20 hours while HUVECs
in which EYA3 levels were reduced were severely compromised in
their ability to form tubes (Figure 1d). Together these data support
a role for EYA3 in endothelial cell remodeling, most likely by
promoting cell migration.
Figure 1. EYA3 knockdown in HUVECs attenuates single cell motility and capillary morphogenesis. (a) Expression of Eya transcripts in
HUVECs. Real-time PCR product was analyzed at saturation (cycle 45) on a 1.5% agarose gel to confirm that amplified products were of the expected
sizes. Indicated are the numbers of amplification cycles after which each signal was detectable; EYA4 was not detected (ND) after 45 cycles of
amplification. RT- stands for cDNA from a reaction without reverse transcriptase. Graph below show the results of quantitative RT-PCR on HUVECs
transduced with lentivirus scramble control RNA or shEYA3. (b) Change in cell density of HUVECs-scramble control and HUVEC-shEYA3 after 24 hours
shows a small but significant increase when EYA3 levels are reduced. (c) Transwell migration of HUVEC-scramble control and HUVEC-shEYA3 shows
a significant reduction in motility when EYA3 levels are reduced. (d) Capillary morphogenesis on matrigel was assayed using HUVEC-scramble control
and HUVEC-shEYA3. A significant reduction in tube formation was seen when EYA3 levels were lowered. In each case the bars represent the mean
and standard error of three experiments. The p-values were calculated by one-way ANOVA followed by a Tukey post test. ns is not significant, *
p,0.05, ** p,0.01, *** p,0.001. In each case the p value shown is relative to the scramble-control.
doi:10.1371/journal.pone.0034806.g001
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tyrosine phosphatase
A specific chemical inhibitor of the EYA tyrosine phosphatase
activity represents a convenient means of querying the role of this
activity in cell motility and angiogenesis while leaving the
transactivation and threonine phosphatase domains unaffected.
Towards this goal we conducted an experimental screen to identify
chemical inhibitors. The National Cancer Institute’s Diversity Set
II Library was screened for inhibitors of the phosphatase activity of
Eya3. Hydrolysis of the model substrate p-nitrophenylphosphate
(pNPP) by the catalytic domain of Eya3 (ED; residues 223–510) in
the presence of 125 mM of each compound was measured. The 30
strongest inhibitors were then tested using full-length human
recombinant, purified EYA3 and pNPP as a substrate. These
screens led to the identification of Benzbromarone (compound 1;
Figure 2) as a potent inhibitor of EYA3’s tyrosine phosphatase
activity. Compound 1 also inhibited the catalytic activity of
EYA2(ED) with comparable potency. These results were mirrored
when an alternate substrate, a 10 amino acid phosphopeptide
representing the C-terminus of the known EYA substrate c-H2AX
[6,7], was used (Figure 2). The inhibitory effect was retained in the
presence of 0.01% Triton X-100, a non-ionic detergent, indicating
that compound 1 was not non-specifically self-aggregating and
sequestering enzyme as has been observed in some cases [26,27].
The catalytic domain of the EYAs also mediates its interaction
with the SIX proteins. This complex then translocates to the
nucleus where the SIX-EYA complex can activate transcription
[28]. To determine whether this series of compounds might
disrupt a representative EYA-SIX interaction we tested the ability
of His-tagged SIX2 to pull-down (using Ni-NTA agarose) EYA3 in
the presence and absence of compound 1. The interaction
appeared to be unaffected by the presence of the EYA inhibitor
(Figure 2d).
To gain a better understanding of how EYA3 might bind
compound 1, we generated a homology model of EYA3(ED) using
the crystal structure of EYA2(ED) bound to BeF3 (3HBO.PDB,
[7,29]) as a template and the SWISSMODEL server [30].
Structure-based alignment of residues 302–573 of EYA3 with
residues 267–568 of EYA2(ED) was used. Residues 356–370 of
Eya2 are not present in the Eya2(ED) crystal structure, pre-
sumably because they are disordered. The corresponding region in
EYA3 (391–405) is omitted from the final model. The proteins
share 67% sequence identity. The resulting homology model was
validated using ANOLEA [31], VERIFY-3D and GROMOS
[30]. These analyses indicated that the molecular geometry of the
model was of good quality. The structure of EYA3(ED) is
comprised of two subdomains: residues 316–458 form the ‘‘cap’’
domain while the rest of the residues make up the ‘‘core’’ catalytic
domain (Figure 3a). The active site (represented by the Mg
2+ ion in
Figure 3a) is at the interface of the two subdomains.
In order to provide a benchmark for modeling the interaction
between EYA and the inhibitors identified here, phospho-tyrosine
was docked into the active site of EYA3(ED) using ICM-Chemist-
Pro developed by Molsoft [32]. The docking was performed with
multiple starting locations for the ligand. Since the EYAs
dephosphorylate the C-terminal phosphotyrosine of c-H2AX
[6,7] a free backbone carboxylate was used. The docked
conformation for the phosphotyrosine ligand is shown in
Figures 3a, b. Non-esterified phosphate oxygens of phosphotyr-
osine coordinate the Mg
2+ ion (2.1 A ˚) and are also within
hydrogen bonding distance of the side-chains for Lys515 and
Thr483. The free carboxylate of the tyrosine residue is positioned
to form hydrogen bonds with side-chains of Thr 322 and Ser 324
at the interface of the cap and core domains; such substrate
anchoring by HAD family phosphotransferases that have a cap
domain is commonly observed. Residues 515, 483, 322 are
identical between the EYAs, while Ser324 is a Thr in other EYA
proteins. Lys515 is in motif III as originally described by analogy
with other haloacid dehalogenase class proteins and Thr483 is
adjacent to the conserved Thr in motif II [2]. Thus, this mode of
phosphotyrosine binding agrees with predictions made by analogy
Figure 2. EYA inhibitor Benzbromarone, compound 1. (a) Compound 1 was identified from a screen of the NCI Diversity Set II library. IC50
values for compound 1 were measured for Eya3(ED), human EYA3 and human EYA2(ED) using as substrates the phosphotyrosine mimic pNPP and
a phosphopeptide representing the last 10 amino acids of H2AX, a known EYA substrate. (b) Substrate titration shows that compound 1 is an
uncompetitive inhibitor of EYA3(ED). Increasing concentration of substrate does not overcome inhibition. Each point represents the mean and
standard deviation of two independent readings. (c) Plots of Vmax and Km as a function of inhibitor concentration show that both values decrease
with increased inhibitor concentration. Values in (c) were derived from nonlinear regression analyses of curves in (b) using PRISM (GraphPad
Software). (d) Compound 1 does not affect the interaction between EYA3 and SIX2. Recombinant purified EYA3 and His-SIX2 were mixed and treated
with either the vehicle control (1% DMSO) (lane 1) or 50 mM compound 1 (lane 5) for 15 minutes at room temperature. The mixture was loaded on
a Ni-NTA column. Beads were washed with 3 column volumes of load buffer (last washes, lanes 2 and 6). Proteins retained on the beads are shown in
lanes 3 and 7. Lanes 4 and 8 are molecular weight markers.
doi:10.1371/journal.pone.0034806.g002
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shared among the EYA proteins.
Next, compound 1 was docked into the active site of EYA3(ED).
The results are shown in Figure 3c. The dibromophenol moiety
inserts into a pocket adjacent to the active-site (as defined by the
divalent metal ion, the nucleophilic Asp309 and the general acid
Asp311), and at the interface of the cap and core domains. This
pocket is lined by the side-chains of residues Glu 312, Thr 313, Ile
316, Ser 324, Tyr 325, Lys 328, Tyr 329, and the loop connecting
the C-terminal b-strand and helix of the ED domain. Hydrogen
bonds to Tyr329 and Ser324 tether the dibromophenol in site I.
Ser 324 also plays a role in phosphotyrosine binding but, as is
apparent from Figure 3a, there is little other similarity between the
modes of pY and inhibitor binding. Notably compound 1 does not
appear to chelate the metal ion or occupy the phosphate-binding
site predicted by the docking of phosphotyrosine in Figure 3 or by
the binding of BeF3 and AlF3 in the published crystal structures
[29]. This suggests that compound 1 may not compete with
phospho-tyrosine for the same site. To test this prediction the
velocity of pNPP (a phosphotyrosine mimic) hydrolysis by
Eya3(ED) in the presence and absence of a range of concentrations
of compound 1 was measured. Figures 2b and 2c show that
Eya3(ED) inhibition by compound 1 was not overcome by
increasing substrate concentrations and is best described by an
uncompetitive inhibition model.
Structure-activity relationships of Compound 1
A set of 10 structurally related compounds (Figure 4) were
purchased and screened for their ability to inhibit the catalytic
activity of Eya3(ED) and full-length EYA3. The results are shown
in Table 1. Compounds 1a and 1b, which retain the basic scaffold
of a phenol and a benzofuran linked by a carbonyl group, had
IC50 values comparable to those of compound 1. Deletion of the
two bromine atoms or increasing the length of the aliphatic
substituent on the benzofuran did not significantly affect the
inhibition. However compounds 1c–1g which lack the phenol and
1h–1j which lack the benzofuran group were significantly worse
inhibitors, suggesting that both moieties are necessary for an active
EYA inhibitor.
EYA inhibitors attenuate cell migration but not cell
proliferation
In previous studies we have shown that the tyrosine phosphatase
activity of Eya3 and Eya2 promotes single cell motility in breast
cancer cells [16]. EYA2 is over-expressed in breast cancers and is
associated with increased metastasis and a poorer outcome [13]. In
order to determine whether the EYA inhibitors were effective in
an established EYA tyrosine-phosphatase-associated cellular
function, we over-expressed either EYA2 or EYA2(mut) (in which
the nucleophilic Asp is replaced by an Asn rendering the enzyme
inactive) in the immortalized, non-transformed mammary epithe-
lial cell line MCF10A. Transwell migration was measured and, as
anticipated, based on previous studies [16], over-expression of
EYA2, but not the tyrosine-phosphatase dead mutant, promoted
cell motility (Fig. 4a). Next the migration of MCF10A(EYA2) cells
in the presence of 7.5 mM of compounds 1, 1a, 1b, and 1c was
measured (Figure 5b). All of them, except 1c, significantly
inhibited cell migration. This effect was dose-dependent
(Figure 5d) and the most effective compound (1a) was able to
reduce cell motility by over 50% at the lowest concentration
(1 mM) tested. Notably, compound 1c, which inhibits PTP1B but
not EYA, had no effect on cell motility. The effect of the EYA
inhibitors on the motility of cells over-expressing the phosphatase-
dead mutant EYA2(mut) was comparable to that observed with
control MCF10A cells (Figure 5c).
This same series of compounds was assayed for their effect on
pNPP hydrolysis catalyzed by the classical Cys-based tyrosine
phosphatase PTP1B. Compounds 1 and 1b showed 4.7–6.5 fold
Figure 3. Binding modes of Benzbromarone and the substrate mimic phosphotyrosine differ. (a) In docking experiments
phosphotyrosine (gold) and compound 1 (yellow) bind at the interface of the cap and core subdomains of the catalytic ED domain of EYA3. (b)
Phosphotyrosine coordinates the active site metal ion and makes hydrogen bonds with residues in all three conserved motifs in the EYAs. (c) Docked
conformation (ICM Score 224.8) of compound 1 docked into the active site of EYA3(ED). The conformation shown here was obtained in multiple
docking experiments conducted with different starting conformations for the ligand. Compound 1 inserts its dibromo-phenol group into
a hydrophobic cavity adjacent to the phosphotyrosine binding site and is anchored by a hydrogen bond with Tyr 329. The carbonyl group forms
a hydrogen bond with Ser 324. Compound 1 is not within bonding distance of the metal ion.
doi:10.1371/journal.pone.0034806.g003
Table 1.
IC50 mM (pNPP)
COMPOUND Eya3(ED) EYA3 PTP1B
1 Benzbromarone 11 8.3 53.8
1a Benzarone 19.2 17.0 .150
1b 10.1 15.2 71.4
1c .150 .150 11.8
1d .150 .150 .150
1e .150 .150 .150
1f .150 .150 102.1
1g .150 .150 .150
1h .150 .150 .150
1i .150 .150 .150
1j .150 .150 .150
doi:10.1371/journal.pone.0034806.t001
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was over 100-fold more specific towards EYA3. On the other hand
compound 1c preferentially inhibited PTP1B.
To assess the cellular toxicity of the compounds and their effect
on cell proliferation, an MTT assay was conducted. Over-
expression of EYA2 or the mutant EYA2(mut) had insignificant
effect on MCF10A cell proliferation (Fig. 5e), and none of the EYA
Figure 4. Structure-activity relationships. Chemical structures of compounds related to Benzbromarone (1a–1j) that were assayed for their
ability to inhibit the phosphatase activity of Eya3(ED), EYA3, and PTP1B. IC50 values are in Table 1.
doi:10.1371/journal.pone.0034806.g004
Figure 5. EYA2 overexpression in MCF10A cells increases cell motility, which in turn is inhibited by EYA inhibitors. (a) Trans-well
migration of MCF10A cells transfected with either pcDNA 3.2/V5-DEST (V5 vector control), V5-EYA2, or the phosphatase dead mutant V5-EYA2(mut).
(b) MCF10A-EYA2 cells were treated with 7.5 mM of compounds 1, 1a, 1b, or 1c. Percentage migration relative to cells treated with the vehicle (0.1%
DMSO) is shown. (c) Transwell migration of MCF10A-EYA2(mut) cells in the presence of 7.5 mM of compounds 1, 1a, 1b, or 1c (d) Relative migration of
MCF10A-EYA2 cell migration by compounds 1, 1a, and 1b when treated with the doses indicated on the x-axis. (e) Change in cell density of MCF10A-
V5 ctl, MCF10A-EYA2 and MCF10A-EYA2(mut) cells after 48 hours measured using the MTT assay. (f) Change in cell density of MCF10A-EYA2 cells
after 48 hours in the presence of either vehicle control (0.1% DMSO) or 10 mM compounds 1, 1a, and 1b. For transwell migration experiments each
bar represents the mean (and standard error) of five random fields per filter and two wells per experiment. For proliferation experiments each bar
represents the mean (and standard error) of three experiments. The p-values were calculated by one-way ANOVA followed by a Tukey post test. ns is
not significant, * p,0.05, ** p,0.01, *** p,0.001. In each case the p value shown is relative to the V5-control or the vehicle-treated sample.
doi:10.1371/journal.pone.0034806.g005
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MCF10A-EYA2 cells (Figure 4f). Together these data suggest that
the EYA tyrosine phosphatase inhibitors 1, 1a and 1b can reduce
the motility of mammary epithelial cells over-expressing EYA2 at
concentrations that are not cytotoxic.
EYA tyrosine phosphatase inhibitors attenuate
endothelial cell motility and tubulogenesis in vitro
We next sought to specifically query the role of the EYA tyrosine
phosphatase activity in endothelial cell migration and angiogenesis.
HUVECs in the presence of compounds 1, 1a, 1b, 1c, or a vehicle
control(0.1%DMSO)wereusedintranswellmigrationassays.Asin
the case ofMCF10A-EYA2cells,allofthese compounds(except1c)
attenuatedHUVECcellmotility(Figure6a).Inparallelexperiments
using MTT no reduction of cell proliferation was observed
(Figure 6b). The EYA inhibitors were also used in tubulogenesis
assays conducted on Matrigel. Compound 1a potently inhibited
tubulogenesis in a dose-dependent fashion, showing nearly 50%
reduction in tube formation at 2.5 mM (Figure 6c). Compounds 1
and 1b were effective only at the highest concentrations tested
(7.5 mM).ThustheEYAinhibitorsareabletoreduceendothelialcell
motility and tube formation.
EYA inhibitors inhibit sprouting angiogenesis in an ex
vivo murine aortic ring assay
To further examine the role of the tyrosine phosphatase activity
and the effectiveness of the inhibitors on vascular maturation and
morphogenesis we used the murine aortic ring assay. In this
protocol angiogenesis is monitored by the formation of vascular
sprouts outside the wall of mouse aortic rings incubated in collagen
matrix and stimulated by VEGF [33]. An extensive microvascular
network with an average maximal sprout length of 900 mm was
observed in both untreated and vehicle-treated (0.1% DMSO)
mouse aortic rings after 10 days (Figure 7a). In contrast, aortic
rings treated with 5 mM of compounds 1, 1a, and 1b exhibited
shorter sprouts and significantly lower microvascular density
(Figure 7a). Moreover this inhibition was dose-dependent
(Figure 7c) and compound 1c had negligible effect. These results
demonstrate that inhibition of EYA tyrosine phosphatase activity
reduces the angiogenic response to VEGF stimulation.
EYA tyrosine phosphatase inhibition has an anti-
angiogenic effect in a zebrafish model
In order to test the possibility that the EYAs are angiogenic in
the more complex, context-driven environment encountered by
blood vessels in vivo we used the well-characterized zebrafish model
of angiogenesis [34,35]. Transgenic fish expressing EGFP in
endothelial cells (Tg(kdrl:EGFP)) [36] were used to facilitate
visualization of the developing vasculature. In control experiments
embryos were treated with 0.1% DMSO (vehicle) starting at
approximately 5 hours post-fertilization (hpf), prior to the
emergence of blood vessels. At the time of analyses (28–30 hpf)
the major axial vessels, the dorsal aorta, the posterior cardinal vein
and intersegmental vessels which branch from the dorsal aorta in
a stereotypical pattern were normally formed (Figure 8b).
Experimental embryos were exposed to varying doses of
compounds 1, 1a and 1b. Dose-dependent defects in the
developing vasculature were observed in all cases (Figure 8a),
ranging from a reduction in intersegmental vessel number and
extension at lower doses to changes in the dorsal aorta and
cardinal vein at higher doses. Representative images are shown in
Figure 8b. Compound 1 (Benzbromarone) was the most potent
showing significant reduction of intersegmental vessels even at the
lowest dose tested (0.25 mM). Benzarone (compound 1a) and 1b
also reduced the number of intersegmental vessels, but were less
potent. When embryos were exposed to the compounds starting at
a later stage (20 hpf) no defects in the vasculature or general
morphology were observed. Compound 1c, which does not inhibit
the EYAs but does inhibit PTP1B, was used as a negative control;
at the highest dose tested (7.5 mM) it showed no effect on the
vasculature. This analysis confirms that Eya plays a role in
promoting developmental angiogenesis and that the EYA
inhibitors are effective in an in vivo experimental system.
Discussion
In this report we demonstrate that Eyes Absent promotes
angiogenesis specifically through its tyrosine phosphatase activity.
While a role for the EYAs in angiogenesis has not been previously
reported, it is not an unexpected observation in light of the
association between the EYAs and cell migration, and the
cardiovascular defects associated with Eya mutations in humans
and in mice. Effects of EYA inhibition were apparent in the
processes of both vasculogenesis (HUVEC capillary tube forma-
tion, formation of the zebrafish aorta and posterior cardinal vein)
and sprouting angiogenesis (aortic ring assay, formation on
intesegmental vessels in zebrafish). Upon bathing zebrafish
embryos in the EYA inhibitors we see a clear effect on vascular
development at doses that do not affect the general morphology,
suggesting a degree of specificity. On the other hand when the
inhibitors were administered relatively late no significant change in
the development of intersegmental vessels was seen. Hence from
the currently available data it is not possible to specify whether the
inhibitors act exclusively on either vasculogenesis or angiogenesis.
In vitro EYA inhibition does not appear to attenuate endothelial
cell proliferation. Hence the pro-angiogenic function of EYA could
be a direct result of its ability to activate a cell migration-
promoting pathway. The EYA substrate involved in this process is
yet to be identified.
However another possibility is that dephosphorylation of H2AX
at Tyr142 [6,7] underlies the pro-angiogenic role played by EYA.
Angiogenesis can be promoted by hypoxia during normal
development as well as in pathological conditions such as
retinopathy of prematurity (ROP), diabetic retinopathy and tumor
angiogenesis (reviewed in [37]). Hypoxia leads to DNA damage
and the phosphorylation of H2AX at Ser139 (to yield c-H2AX) by
ATR kinases. Re-oxygenation and the production of reactive
oxygen species lead to double-strand breaks and the formation of
c-H2AX though the action of ATM kinase. Recent evidence
suggests that such activation of H2AX contributes to angiogenesis
and proliferative retinopathies[38]. The constitutively Tyr142-
phosphorylated form of H2AX [39] promotes recruitment of the
p53 apoptosis machinery and disfavors DNA damage repair [6].
Activation of ATM/ATR also leads to EYA activation and
dephosphorylation of H2AX-pY142, thus permitting DNA repair
[6,7]. Hence hypoxia-induced angiogenesis could be promoted by
the tyrosine phosphatase activity of the EYA proteins via
dephosphorylation of H2AX-pY142. In this manner EYA is likely
to play a role in both developmental and pathological retinal
angiogenesis.
In this study small molecule inhibitors of the Eyes Absent
tyrosine phosphatase activity were used as chemical probes of
EYA’s cellular function because they permit separation of EYA’s
signal transduction and transcriptional activities. However the
inhibitors also have other potential uses. The growing evidence
that EYAs are over-expressed in malignancies raises the possibility
that inhibitors could be a targeted therapy for appropriate subsets
EYA Is Pro-Angiogenic, Inhibited by Benzbromarone
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nerve sheath tumors [13,14,15,16]. Furthermore, since the EYA
PTP activity promotes DNA damage repair [7], it is likely that
EYA inhibitors could potentiate commonly used genotoxic
therapeutic regimens such as chemotherapy and ionizing radia-
tion.
Interestingly Benzbromarone was also identified in an early
screen for PTP1B inhibitors [40], and more detailed analyses and
crystallographic studies of Benzbromarone-derivatives were later
reported [41]. These compounds bind to an allosteric site on
PTP1B far from the active site and are noncompetitive inhibitors
that prevent formation of the active ‘‘closed’’ conformation of the
enzyme. In contrast our studies suggest that Benzbromarone binds
in a hydrophobic pocket adjacent to the active site of EYA, and it
is not competitive with small substrate mimics such as pNPP and
phosphotyrosine. Furthermore both the docking studies (Figure 3)
and kinetic analyses (Figure 2) demonstrate that, despite the
presence of a phenol group in all of the EYA inhibitory
compounds in Figure 4, they are unlikely to be acting as simple
tyrosine-mimics. Inhibition of both EYA3 and EYA2 were tested
in this analysis and the compounds are similarly effective. This
result is not surprising given the high degree of sequence
conservation in the predicted inhibitor binding sites. Analyses of
benzbromarone related compounds in Figure 4 has also permitted
a separation of the chemical scaffolds necessary for EYA inhibition
versus PTP1B inhibition; compound 1a is preferentially an EYA
inhibitor while compound 1c is a PTP1B inhibitor. These data
thus provide a basis for the design of more potent and selective
EYA inhibitors.
EYA is a metallo-enzyme [2,22,42]. However the inhibitors
described here are not metal-chelators, unlike compounds
identified in a recently reported in silico screen performed using
the isolated catalytic domain of EYA2 [43]. While metal chelators
can be high affinity inhibitors of metalloenzymes, as therapeutics
they present challenges such as depletion of physiologically needed
metal ions and inhibition of non-targeted metalloenzymes. Hence
the identification of EYA inhibitors that do not appear to
coordinate the active site divalent metal in the EYAs opens up
new possibilities.
Figure 6. EYA inhibitors attenuate migration and tubulogenesis of HUVECs. (a) Percent migration of HUVECs in the presence of 5 mM
relative to the vehicle control?. (b) Change in cell density after 24 hours in the presence of either vehicle control (0.1% DMSO) or 5 mM of each EYA
inhibitor. (c) Quantitation of the number of tube-like structures formed by HUVECs in the presence of either the vehicle control (0.1% DMSO) or the
indicated concentrations of compounds 1, 1a and 1b. The number of tubes was measured using NeuroJ. Data are mean and standard error of three
independent experiments. p-values from a one-way ANOVA are shown; ns is not significant, * p,0.05, ** p,0.01, *** p,0.001. (d) Representative
images of HUVECs on Matrigel in the presence of the indicated doses of 1a.
doi:10.1371/journal.pone.0034806.g006
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are both known uricosuric agents. They suppresses uric acid
reabsorption via inhibition of the urate transporter SLC22A12
(URAT1) [44]. The compounds have a short half-life (about
3 hours [45]), but their major metabolite 6-hydroxybenzbromar-
one has a longer half-life of 30 hours and retains the uricosuric
activity. These compounds are no longer marketed for use in the
treatment of gout in most countries because of reported
hepatotoxicity and their ability to inhibit CYP2C9 which causes
undesired interactions with drugs that use this enzyme for
clearance, such as warfarin (reviewed in [46]). However there
remains controversy about whether the benefit-risk ratio warrants
a complete withdrawal [47]. There have been no previous reports
of either compound affecting cell motility or angiogenesis. Hence
the data presented here represents an opportunity for re-purposing
a well-characterized drug as an anti-angiogenic and anti-
metastatic agent.
In summary we have identified a class of compounds that
strongly inhibit the EYA tyrosine phosphatases. These compounds
display selectivity towards EYA relative to a representative
classical PTP, PTP1B. The inhibitors effectively attenuate the
known ability of the EYAs to promote cell motility and have been
used as a tool to reveal a pro-angiogenic function for the EYA
tyrosine phosphatase. These inhibitors could thus be useful in
identifying other biological role(s) of this multi-tasking protein, as
well as in probing the molecular mechanisms by which it
functions. The compounds also represent viable leads for the
development of EYA-targeted therapeutics with potential uses in
the treatment of cancer metastasis, potentiating DNA damaging
chemotherapy, tumor angiogenesis, as well as other vasculopa-
thies.
Materials and Methods
Ethics Statement
All animal use and experimentation was in accordance with
protocols approved by Cincinnati Children’s Hospital Medical
Center’s Institutional Animal Care and Use Committee. 4–6 week
old C57BL/6 mice were obtained from the Jackson Labs (Bar
Harbor, Maine) and housed in the Cincinnati Children’s Hospital
Animal Facility.
shRNA mediated mRNA depletion
HUVECs were incubated overnight with shEYA3 or scramble
control lentiviral suspension in the presence of 8 mg/ml polybrene.
The next day, viral suspension was replaced by fresh medium.
24 hrs later, cells were selected with 2 mg/ml puromycin until
control cells were all dead (after 72 hrs of selection). To measure
expression of Eya transcripts in HUVECs total RNA was
extracted from 1000,000 HUVECs, cDNA was synthesized from
2 mg of total RNA using the Superscript III kit (Invitrogen) in
a total volume of 30 ml. cDNA was diluted with nuclease free
water to 180 ml. 5 ml of the diluted cDNA was used for real-time
PCR. PCR product was analyzed at saturation (cycle 45) on a 1.5%
agarose gel to confirm that amplified products were of the
expected sizes. Indicated are the numbers of amplification cycles
after which each signal was detectable; EYA4 was not detected
(ND) after 45 cycles of amplification. RT- stands for cDNA from
a reaction without reverse transcriptase. Primers used are listed
below.
hEYA1: CACGATGCTAATCCGGAAAT and AA-
TATTGCCCAGCCAAACTG
Location on cDNA: 3322–3459
hEYA2: GATTCGGCAGAAAAGCTGTC and
CTGGGTCTCTGGAGTTCTCG; Location on cDNA: 1606–
1840
Figure 7. EYA inhibitors attenuate sprouting angiogenesis. (a) Representative images of aortic rings treated with either the vector control
(0.1% DMSO) or 5 mM of compounds 1, 1a, or 1b. Rings were stained with isolectin. 1c is used as a negative control as it does not inhibit EYA. (b)
Quantitation of the number of sprouts per ring is included; each bar represents the mean of 6 rings. p-values from a one-way ANOVA are shown; ns is
not significant, * p,0.05, ** p,0.01, *** p,0.001. (c) Compounds 1, 1a, and 1b in the indicated doses were used in aortic ring experiments. The
number of sprouts per ring is plotted indicating that inhibition of aortic sprouting was dose-dependent.
doi:10.1371/journal.pone.0034806.g007
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CCTCAACCCAAGACACACCT; Location on cDNA: 4913–
5151
hEYA4: TGCTAAGTCTGTGGGTGCAG and
GTTCTCCGTCAACCTTGCAT; Location on cDNA: 4666–
4826
GAPDH: CGACCACTTTGTCAAGCTCA and
AGGGGTCTACATGGCAACTG; Location on cDNA: 964–
1191
Transwell migration assays
Human umbilical vein endothelial cells (HUVECs) were
purchased from Lonza (Walkersville, MD) and maintained in the
endothelial cell growth medium (PromoCell, Heidelberg, Ger-
many), under a 5% CO2 atmosphere. MCF10A cells from ATCC
were stably transfected with either pcDNA 3.2/V5-DEST (vector
control), V5-EYA2 or V5-EYA2(mut). Transwell migration
experiments were performed as previously described [16].
Cell proliferation assay
HUVEC cells were plated at 2,000 cells/100 ml/well in
a collagen I coated 96-well plate and cultured at 37uCi n
a humidified incubator in the presence of 5% CO2. For each
condition and time point, the culture was set up in triplicate. After
the desired incubation time, the number of viable cells was
estimated using the cell counting kit-8 (Dojindo Molecular
Technologies, Rockville, MD). The cell density was expressed as
the mean absorbance at 450 nm.
Tubulogenesis assay
Tubulogenesis assays were performed in 15-well micro-slide
(ibidi LLC, Verona WI), using growth factor-reduced matrigel (BD
Bioscience, Billerica, MA). The matrix was prepared by loading
10 ml of matrigel in each micro-slide well and allowing it to solidify
for 30 minutes at 37uC. HUVECs were trypsinized and
resuspended at 100,000 cell/ml in EBM +2.5% FBS. 50 ml
(5,000 cell) were loaded on top of the solidified matrigel and the
preparation was incubated for 20 hours at 37uC in a humidified
incubator in a 5% CO2 atmosphere. Bright field images were
taken using an inverted microscope at 2.56magnification, which
allowed imaging of the whole well in two pictures that were later
merged in Photoshop. Tubular structures were traced and counted
using NeuroJ (NIH, USA). In experiments with inhibitor, the
inhibitor was added to the cell suspension before loading. Each
sample was loaded in triplicate, and each treatment was repeated
for reproducibility.
Purification of recombinant proteins
The catalytic domain (ED) of mouse Eyes Absent 3 (Eya3(223–
510)) was purified as described before [42]. Human Eyes Absent 3
isoform 2 (representing the major species identified in human cell
lines by mass spectrometry [48] and residues 127–573 of
NM_001990, isoform 1) was sub-cloned into pDEST565 to
express a poly-histidine- Glutathione-S-transferase (His-GST)
tagged fusion protein with a TVMV protease site. The protein
was purified by glutathione-S-transferase affinity chromatography
followed by TVMV cleavage, Ni-NTA chromatography, and
finally size exclusion chromatography.
The catalytic domain of human Eyes Absent 2 was similarly
sub-cloned as a poly-histidine fusion construct in the vector
pDEST-527. Fusion protein was purified by Ni-NTA chromatog-
raphy and followed by size-exclusion chromatography over
a Superdex-75 column. The relative purity of protein samples
was determined using SDS-PAGE. PTP1B was purified as
described previously [2].
Inhibitor Screen
The NCI Diversity Set II was obtained from the NCI in 96-well
trays from the NIH Molecular Libraries Program and stored as
10 mM stocks in DMSO. An initial manual screen was conducted
using the previously described p-nitrophenylphosphate assay [2]
and mouse Eya3(223–510) in a reaction mixture containing
20 mM MES pH 6, 2 mM MgCl2, 125 mM inhibitor, 3.4 mM
para-nitrophenol phosphate (pNPP) and 0.01 mg/mL enzyme. The
amount of 4-nitrophenol (pNP) produced was monitored at
405 nM on a BioTek EL808 plate reader. A similar protocol
was used to screen for inhibitor activity using hEYA3 and
hEYA2(ED).
IC50 determination
Compound 1a was obtained from Sigma-Aldrich (cat. no.
L129305) and compounds 1b–1j from ChemDiv (cat. nos. 3039-
0682; 4237-0212; 6526-0043; 6526-0210; 8005-2108; 8009-4552;
0831-0939; 8005-2010; R052-0049). Compounds were dissolved
in DMSO and diluted as needed. IC50 values were determined by
adding varying amounts of inhibitor (0–400 mM) to reaction
mixtures containing 20 mM MES pH 6, 2 mM MgCl2, 2%
Figure 8. Dose-dependent effects of EYA inhibitors on the
developing zebrafish vasculature. (a) Titration of compounds 1, 1a,
1b at the indicated doses. Two independent experiments were
performed in most cases using 9–15 embryos per experiment at each
dose; the standard error and mean values are shown. Experiments with
0.25 mM compound 1 and 5 mM compound 1b were only performed
once using 10 embryos each. The y-axis shows the percentage of
embryos showing any defects in vascular development (either in-
tersegmental vessels (ISV) formation or defects in the dorsal aorta/
cardinal vein). (b) Images of representative untreated control (CTL),
vehicle (DMSO) treated, and EYA inhibitor treated embryos at 28–
30 hpf. Note reduced or absent ISV in the inhibitor treated embryos
relative to the controls (ISV in controls indicated by white arrows).
doi:10.1371/journal.pone.0034806.g008
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incubated at 30uC for 30 minutes and quenched with 100 mM
EDTA pH 10. IC50 values were then calculated directly from
regression curves using PRISM. All reported values are the mean
of two independent experiments.
Peptide-based assays
The phospho-peptide KKATQASQEpY was obtained from
Genscript. Peptide assays were conducted in 20 mM MES pH 6.5,
25 mM NaCl, 2 mM MgCl2, and a range of peptide concentra-
tions from 0 to 300 mM as previously described [2]. IC50 values
were then calculated in PRISM.
Docking
Compound 1 was docked into the active site of EYA3(ED) using
ICM Chemist Pro (Molsoft L.L.C.) with flexible ligand and rigid
target. The formal charge on the Mg ion was set to +0.66. Once
the ligand was docked into the active site the side-chains lining the
binding pocket were refined and the ligand re-docked. A stack of
docking conformations were generated and visually assessed. The
orientation of compound 1 shown in Figure 2 represents a cluster
with an ICM Score =224.8 that was significantly better than all
of the other clusters.
Mouse Aortic ring assay (ARA)
The preparation of rat collagen and the aortic ring assay were
carried out as previously described [49,50]. Mice were 4 to 6 week
old female C57BL/6, and aortic ring explants were cultured at
37uC in a humidified incubator under a 5% CO2 atmosphere.
Each inhibitor was serially diluted (between 0.25 mM and
7.5 mM) to stocks of 10006the working concentrations in sterile
100% DMSO in order to achieve an equal final concentration of
DMSO (0.1% v/v) in all culture conditions. For the experiments,
the compounds were diluted in EBM containing 2.5% FBS,
penicillin/streptomycin and 20 ng/ml VEGF165 (R&D Systems,
Minneapolis, MN). Each compound was applied from the first day
of culture over a 10-day period with medium change every two
days. In all experiments, the vehicle (DMSO, 0.1%) was used as
control. The sprouting density was derived from counting the
number of branches per ring, and the extent of angiogenic
sprouting was estimated by measuring the total surface area
covered by the vessels.
Analysis of zebrafish vasculature
Tg(kdrl:EGFP)
s843 zebrafish line was used for vascular analysis.
Embryos were maintained in fish water until the 50% epiboly
stage (5.25 hpf) and were transferred into wells of 24-well plate
containing the inhibitors in fish water. All incubation was
performed at 28.5uC. The analysis for vascular defects was
performed at the 28–30 hpf stages, and embryos were imaged
using a fluorescence microscope.
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